Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Chief Commercial Officer | January 10, 2025 | April 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date January 10, 2025 · Filed April 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 900,682 |
Reported balance
After 2025-01-10 transaction · row 1
1 source rowRow 1 · 2025-01-10 · Exercise / conversion · Acquired 958 · Balance 900,682 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2025-01-12 | Direct | 0 |
Reported balance
After 2025-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-10 · Exercise / conversion · Disposed 958 · Balance 0 F1: 100% of the shares subject to the option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 4,060 | Not disclosed Strike: $2.47 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 8 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,060 Underlying: Common Stock · 4,060 shares Expires 2025-08-11 F10 · price: Received in connection with the Merger in exchange for an option to acquire 2,000 shares of common stock of Organogenesis for $5.00 per share. F9 · derivative.exercise_date: The shares underlying the option vested or shall vest 25% annually beginning on August 11, 2016. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 958 | Not disclosed Strike: $1.24 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 7 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958 Underlying: Common Stock · 958 shares Expires 2025-01-12 F8 · price: Received in connection with the Merger in exchange for an option to acquire 472 shares of common stock of Organogenesis for $2.50 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 805 | Not disclosed Strike: $4.49 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 6 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805 Underlying: Common Stock · 805 shares Expires 2023-07-17 F7 · price: Received in connection with the Merger in exchange for an option to acquire 397 shares of common stock of Organogenesis for $9.10 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 805 | Not disclosed Strike: $1.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 5 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805 Underlying: Common Stock · 805 shares Expires 2022-08-21 F6 · price: Received in connection with the Merger in exchange for an option to acquire 397 shares of common stock of Organogenesis for $2.95 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 958 | Not disclosed Strike: $1.44 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 4 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958 Underlying: Common Stock · 958 shares Expires 2021-10-17 F5 · price: Received in connection with the Merger in exchange for an option to acquire 472 shares of common stock of Organogenesis for $2.92 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 1,151 | Not disclosed Strike: $1.70 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2020-04-15 F4 · price: Received in connection with the Merger in exchange for an option to acquire 567 shares of common stock of Organogenesis for $3.45 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 667 | Not disclosed Strike: $1.70 | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2019-10-02 F3 · price: Received in connection with the Merger in exchange for an option to acquire 329 shares of common stock of Organogenesis for $3.45 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:30 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantCommon Stock | 1,462 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001661181-18-000041 · edgar.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,462 F1 · price: Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for 720 shares of common stock of Organogenesis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.